Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) issued its quarterly earnings results on Monday. The company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.18 by $0.18, Zacks reports. The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.47%.
Shionogi & Co., Ltd. Unsponsored ADR Stock Performance
Shares of SGIOY opened at $8.78 on Wednesday. The company’s fifty day moving average is $8.82 and its 200-day moving average is $9.88. Shionogi & Co., Ltd. Unsponsored ADR has a 12 month low of $7.65 and a 12 month high of $12.00. The firm has a market cap of $14.93 billion, a price-to-earnings ratio of 10.97, a price-to-earnings-growth ratio of 3.71 and a beta of 0.08. The company has a quick ratio of 1.46, a current ratio of 1.58 and a debt-to-equity ratio of 0.01.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on SGIOY shares. The Goldman Sachs Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 15th. Jefferies Financial Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Finally, Zacks Research raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research note on Monday, May 25th. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy”.
Shionogi & Co., Ltd. Unsponsored ADR Company Profile
Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.
The company’s product portfolio spans both established and innovative therapies.
See Also
- Five stocks we like better than Shionogi & Co., Ltd. Unsponsored ADR
- Caterpillar’s Record Quarter May Have Reset the Stock’s Ceiling
- The Real Reason Amazon Hit a $3 Trillion Valuation
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
